Fatty Acid Synthase Enzyme Activity Research Articles

Abstract 10628: The Role of Hepatic Endoplasmic Reticulum Homeostasis in Liver-Heart Crosstalk in Sepsis

The heart demands continuous supply of energy substrates, primarily in the form of lipids, to sustain its contractility and other functions. During episodes of severe stress such as sepsis, an overwhelming pathogen-induced systemic immuno-metabolic response, the heart heavily relies on lipid particles synthesized at the endoplasmic reticulum in the liver. However, it is currently unknown how this lipid-dependent crosstalk supports cardiac function during stress and how it is regulated in the liver. In this study, we employed proteomic, lipidomic, and metabolomic approaches to show that hepatic Inositol-Requiring Enzyme 1 α (IRE1α), a key regulator of ER homeostasis, interacts with and regulates the activity of Fatty Acid Synthase (FAS), a well-known enzyme that synthesizes lipids. Notably, this dynamic physical interaction was disrupted in the setting of experimental sepsis induced by lipopolysaccharide (LPS). Specific deletion of IRE1α in the liver sensitized mice to LPS-associated mortality due to cardiac dysfunction. Mechanistically, we found that loss of IRE1 did not alter hepatic or systemic cytokine response, but suppressed FAS enzymatic activity, compromising the adaptive hepatic lipid metabolic reprogramming in response to the LPS challenge. Notably, IRE1α deletion diminished the LPS-induced lysophosphatidylcholine (LPC) secretion from the liver, a critical lipid species that is positively correlated with survival in septic human patients. In turn, this impaired hepatic ER-mediated lipid reprogramming contributed to cardiac dysfunction in part through reducing cardiac oxygen consumption and promoting neutrophil infiltration in response to sepsis. Together, our study provides the first insight into how adisruption of hepatic ER-mediated lipid metabolic regulation promotes sepsis-associated cardiac immuno-metabolic imbalance. Knowledge gained from this study might speed the development of novel therapeutic targets for hepatic ER homeostasis in sepsis-associated heart dysfunction.

Abstract 2455: A potential FASN -IGF1R signaling loop in breast cancer

Abstract Background: The overexpression of the IGF-1R is correlated with an overall worse prognosis for breast cancer patients. IGF-1R contributes to an aggressive phenotype through its downstream signaling cascades, including the classical PI3K-Akt- mTORC1 pathway. Recent studies suggest another important target of IGF-1R regulation is the fatty acid synthase enzyme (FASN), leading to increased endogenous fatty acid synthesis. The importance of FASN activity to breast cancer progression is illustrated by the success of recent clinical trials investigating the efficacy of FASN inhibitors in refractory breast cancer. Previous studies in our lab and others have identified SREBP and SRPK2 as key IGF-1R targets regulating FASN expression. FASN expression can lead to excess palmitate, which can serve as a substrate for palmitoylation shown to aid in the membrane localization and function of various receptor tyrosine kinases, including IGF-1R. However, the role of FASN induced localization and activation of IGF-1R in breast cancer has not been investigated and is critical for a better understanding of the role of FASN in breast cancer progression. Objective: The goal of this study is to investigate a potential feedforward signaling loop between IGF-1R and FASN and its contribution to breast tumorigenesis. Methods: The impact of suppression of mTOR, SREBP, and SRPK2 on FASN gene expression in response to IGF-1 stimulation in MCF-7 and T47D ER+ breast cancer cells over a course of time was evaluated using qPCR. The role of FASN in IGF-1R stabilization and signaling was determined in MCF-7 cells pretreated with 2-bromopalmitate (2-BP, a palmitoylation inhibitor) or the FASN inhibitor, TVB-3166. Colony formation and migration assays were performed for phenotypic analysis of breast cancer cells in response to IGF-1R and SRPK2 modulation. Results: Inhibition of mTORC1 resulted in an attenuation of FASN expression in both MCF-7 and T47D cells upon IGF-1 exposure. Additionally, inhibition of palmitoylation and/or FASN resulted in a decreased stabilization and activation of IGF-1R in MCF-7 breast cancer cells. Further elucidation of specific mechanisms of post-transcriptional regulation of FASN through SRPK2 as well as effects of SRPK2 and IGF-1R inhibition on breast cancer cell migration and survival are on-going. Conclusion: The results of this study suggest that a potential mechanism of breast cancer progression is through an autoregulatory loop between IGF-1R signaling and FASN activity, which can be effectively limited using the new class of FASN inhibitors. These data support the rationale for continued clinical studies evaluating the efficacy of FASN inhibitors in breast cancers driven, at least in part, by IGF-1 signaling. Citation Format: Bryan McClellan, Brittany Harlow, Christopher Jolly, Linda deGraffenried. A potential FASN -IGF1R signaling loop in breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2455.

Effect of different sources and forms of dietary carbohydrates on growth performance, body indices and lipogenesis activity of striped catfish Pangasianodon hypophthalmus fingerlings

A 12‐week feeding trial was conducted to determine a suitable carbohydrate source and form for Pangasianodon hypophthalmus. Ten isoenergetic, isonitrogenous and isolipidic diets, including five carbohydrate sources (dextrin, potato starch, wheat starch, corn starch and sago starch) and two carbohydrate forms (raw and cooked), were formulated. Results showed that specific growth rate, weight gain percentage, whole‐body lipid and 6‐phosphogluconate dehydrogenase enzyme activity of fish fed with cooked carbohydrates were significantly lower (p < .05) than those fed with raw carbohydrates (p < .05). Similarly, the fatty acid synthase enzyme activity of fish fed with the cooked form of carbohydrates was significantly lower (p < .05) than that fed with the raw form of carbohydrates except fish fed with cooked potato starch. The blood glucose level and malic enzyme activity of fish fed with cooked carbohydrate were significantly (p < .05) higher than those fed with raw carbohydrate. In summary, this study showed that cooked starch is an unsuitable dietary carbohydrate form for Pangasianodon hypophthalmus fingerlings. The raw forms of dextrin starch and potato are suitable dietary carbohydrate sources for further scientific studies on the carbohydrate utilization of P. hypophthalmus.

Evidence for the existence of de novo lipogenesis in goose granulosa cells

De novo lipogenesis (DNL) is an important physiological mechanism, but it is poorly understood in avian follicles. The protein distribution patterns of three key genes related to DNL (i.e., FAS, ACC, and PPARγ) were firstly determined in geese developing follicles using immunohistochemistry, and our results showed that all three proteins were present in both prehierarchical and hierarchical follicles. Furthermore, it was revealed by qPCR that transcripts of these three genes were widely expressed in theca and granulosa layers of all staged follicles; however, the expression of DNL-related genes in granulosa cell changed significantly (P < 0.05) after follicle selection (FAS and PPARγ) and before ovulation (FAS). It is suggested that the DNL mechanism may be closely related to the follicular selection, while FAS may be closely associated with ovulation and steroidogenesis. These results suggested that DNL exists throughout follicle development and it potentially have an important role in the process of follicular selection, development, steroidogenesis, and ovulation, especially in their granulosa layers. To further demonstrate this point, granulosa cells isolated from hierarchical follicles were cultured in vitro. By analyzing the mRNA and protein expression patterns of these three genes, the fatty acid synthase enzyme activity, the contents of extracellular triglyceride, and intracellular lipids, as well as the cell activity at different time points of in vitro culture (0, 6, 12, and 18h). These findings not only ensured the existence of DNL in the granulosa cells of goose follicles, but also suggested the complex process of lipid metabolism that associated with DNL, may play an important role in cell proliferation and physiological functions. Taken together, we first confirmed the existence of lipid metabolism, especially the DNL in goose follicles, and further suggested its role in the follicles, especially in the granulosa cells.

Anthocyanins from Purple Corn Ameliorated Tumor Necrosis Factor-α-Induced Inflammation and Insulin Resistance in 3T3-L1 Adipocytes via Activation of Insulin Signaling and Enhanced GLUT4 Translocation.

The aim was to compare the effect of an anthocyanin-rich extract from purple corn pericarp (PCW) and pure anthocyanins on adipogenesis, inflammation, and insulin resistance in 3T3-L1 adipocytes on basal and inflammatory conditions. Preadipocytes (3T3-L1) were treated during differentiation with or without PCW. Differentiated adipocytes were treated either individually or in combination with tumor necrosis factor α (TNF-α) and PCW, or pure C3G, Pr3G, P3G. PCW reduced preadipocyte differentiation (IC50 = 0.4 mg/mL). PCW and pure anthocyanins including C3G reduced fatty acid synthase enzymatic activity. PCW reduced TNF-α-dependent inflammatory status increasing adiponectin (39%), and decreasing leptin (-79%). PCW and C3G increased glucose uptake and reduced reactive oxygen species generation in insulin resistant adipocytes. An increase in phosphorylation was observed in AKT, IKK, and MEK, and a decrease in IRS and mTOR activating the insulin receptor-associated pathway. PCW (7.5-fold) and C3G (6.3-fold) enhanced GLUT4 membrane translocation compared to insulin resistant adipocytes. Anthocyanins from colored corn prevented adipocyte differentiation, lipid accumulation, and reduced PPAR-γ transcriptional activity on adipocytes in basal conditions. Ameliorated TNF-α-induced inflammation and insulin resistance in adipocytes via activation of insulin signaling and enhanced GLUT4 translocation suggesting a reduced hyperglycemia associated with the metabolic syndrome.

Inhibitory effect of emodin on fatty acid synthase, colon cancer proliferation and apoptosis.

Fatty acid synthase (FASN) is a key anabolic enzyme for de novo fatty acid synthesis, which is important in the development of colon carcinoma. The high expression of FASN is considered a promising molecular target for colon cancer therapy. Emodin, a naturally occurring anthraquinone, exhibits an anticancer effect in various types of human cancer, including colon cancer; however, the molecular mechanisms remain to be fully elucidated. Cell viability was evaluated using a Cell Counting Kit-8 assay. The apoptosis rate of cells was quantified via flow cytometry following Annexin V/propidium iodide staining. FASN activity was measured by monitoring oxidation of nicotinamide adenine dinucleotide phosphate at a wavelength of 340 nm, and intracellular free fatty acid levels were detected using a Free Fatty Acid Quantification kit. Western blot analysis and reverse transcription-polymerase chain reaction were used to detect target gene and protein expression. The present study was performed to investigate whether the gene expression of FASN and its enzymatic activity are regulated by emodin in a human colon cancer cell line. Emodin markedly inhibited the proliferation of HCT116 cells and a higher protein level of FASN was expressed, compared with that in SW480, SNU-C2A or SNU-C5 cells. Emodin significantly downregulated the protein expression of FASN in HCT116 cells, which was caused by protein degradation due to elevated protein ubiquitination. Emodin also inhibited intracellular FASN enzymatic activity and reduced the levels of intracellular free fatty acids. Emodin enhanced antiproliferation and apoptosis in a dose- and time-dependent manner. The combined treatment of emodin and cerulenin, a commercial FASN inhibitor, had an additive effect on these activities. Palmitate, the final product of the FASN reaction, rescued emodin-induced viability and apoptosis. In addition, emodin altered FASN-involved signaling pathways, including phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinases/extracellular signal-regulated kinases 1/2. These results suggested that emodin-regulated cell growth and apoptosis were mediated by inhibiting FASN and provide a molecular basis for colon cancer therapy.

Abstract 2535: Structure-activity relationships of novel N-benzoyl arylpiperidine and arylazetidine FASN inhibitors

Abstract De novo synthesis of fatty acids in mammalian cells is catalyzed by Fatty Acid Synthase (FASN), a complex dimeric protein with seven catalytic domains that processes acetyl-CoA and malonyl-CoA into palmitic acid. Palmitate and other fatty acids are essential for normal physiological processes like energy storage and production and are key intermediates in the biosynthesis of hormones and other essential biomolecules. The role of FASN in cancer has been well documented over the past decade. While FASN is expressed at low levels in most normal tissue (except liver and adipose tissue), it is highly expressed in many tumors including prostate, breast, and colon. FASN overexpression and activity is correlated with poor prognosis and disease progression. Numerous publications describing anti-cancer effects of small molecule FASN inhibitors have appeared in the scientific and patent literature. Recently, several groups reported anticancer and antiviral activities of N-benzoyl arylpiperidine FASN inhibitors. In this work we describe the discovery of novel N-benzoyl arylpiperidine and arylazetidine compounds that potently inhibit FASN enzymatic activity in vitro and antiproliferative activity in FASN-sensitive cell lines. We conducted focused structure-activity (SAR) studies exploring the benzoyl group and the aryl substituent on the piperidine or azetidine heterocycle to optimize potency, improve properties and oral bioavailability, and achieve in vivo FASN-driven pharmacodynamic (PD) activity. X-ray crystal structures of these molecules confirm a unique binding mode within the KR subdomain of FASN. Using structural information and molecular modeling, we were able to rationalize SAR trends and design FASN inhibitors with excellent in vitro potency and cellular activity. These efforts resulted in the discovery of compounds exemplified by JNJ-54380482, a potent FASN inhibitor (IC50 = 26 nM) that inhibits proliferation of A2780 ovarian cells in lipid-reduced medium (LRM, IC50 = 8.9 nM). Engagement of FASN in cellular assays is confirmed by rescue of proliferation upon addition of palmitate. JNJ-54380482 is orally bioavailable in mice (F% = 51) and exhibits excellent plasma exposure when dosed at 10 mg/kg (Cmax = 2.6 µM, T1/2 = 5 h). In a PD study using H460 lung xenograft-bearing mice, oral treatment with 30 mg/kg of JNJ-54380482 results in 36-fold higher tumor levels of malonyl-CoA vs vehicle. In summary, we synthesized several hundred compounds having the N-benzoyl arylpiperidine and arylazetidine chemotypes. Utilizing structural information from X-ray co-crystals to understand SAR and guide the design of more potent molecules, we identified &amp;gt;100 analogs with highly potent FASN enzymatic (IC50 ≤ 50 nM) and antiproliferative activities in A2780 cells in LRM (IC50 ≤ 100 nM). Key examples from these series have good in vitro properties, are orally bioavailable, and demonstrate FASN target engagement in a mouse PD model. Citation Format: Peter J. Connolly, Gilles Bignan, James Bischoff, Sabine De Breucker, Norbert Esser, Erwin Fraiponts, Ron Gilissen, Bruce Grasberger, Boudewijn Janssens, Tianbao Lu, Donald Ludovici, Lieven Meerpoel, Christophe Meyer, Michael Parker, Danielle Peeters, Carsten Schubert, Karine Smans, Luc Van Nuffel, Peter Vermeulen. Structure-activity relationships of novel N-benzoyl arylpiperidine and arylazetidine FASN inhibitors. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2535. doi:10.1158/1538-7445.AM2014-2535

Modulation of Fatty Acid Synthase Enzyme Activity and Expression during Hepatitis C Virus Replication

The hepatitis C virus (HCV) induces alterations of host cells to facilitate its life cycle. Fatty acid synthase (FASN) is a multidomain enzyme that plays a key role in the biosynthesis of fatty acids and is upregulated during HCV infection. Herein, we applied activity-based protein profiling (ABPP) that allows for the identification of differentially active enzymes in complex proteomic samples, to study the changes in activity of FASN during HCV replication. For this purpose, we used an activity-based probe based on the FASN inhibitor Orlistat, and observed an increase in the activity of FASN in the presence of a subgenomic and a genomic HCV replicon as well as in chimeric SCID/Alb-uPA mice infected with HCV genotype 1a. To study the molecular basis for this increase in FASN activity, we overexpressed individual HCV proteins in Huh7 cells and observed increased expression and activity of FASN in the presence of core and NS4B, as measured by western blots and ABPP, respectively. Triglyceride levels were also elevated in accordance with FASN expression and activity. Lastly, immunofluorescence and ABPP imaging analyses demonstrated that while the abundance and activity of FASN increases significantly in the presence of HCV, its localization does not change. Together these data suggest that the HCV-induced production of fatty acids and neutral lipids is provided by an increase in FASN abundance and activity that is sufficient to allow HCV propagation without transporting FASN to the replication complexes.

Overexpression of Fatty Acid Synthase as a Potential Therapeutic Target in Classical Hodgkin Lymphoma

Fatty acid synthase (FASN) overexpression and role in tumorigenesis has been established. The increase in FASN enzyme activity may be associated with tyrosine kinases, including c-Met, which encodes hepatocyte growth factor receptor (HGFR). Teofili et al described a c-Met/HGF interaction in classical Hodgkin lymphoma (cHL), which sustains Hodgkin Reed-Sternberg (HRS) cells in a background of HGF-producing …

Effect of conjugated linoleic acid on fatty acid synthesis in soy and coconut oil fed mice

Dietary conjugated linoleic acid (CLA) causes a body fat loss, which is enhanced when mice are fed coconut oil (CO), in part due to increased lipolysis. Our objective was to determine the effect of CLA supplementation on the mRNA expression of genes involved in fatty acid synthesis in mice fed soy oil (SO) or CO. Male mice (ICR; n=80; 3 wk‐old) were fed 7% SO or CO diets for 6wk, then 0 or 0.5% CLA for 3,7,10, or 14d. The liver relative mRNA expression of Fatty Acid Synthase (FAS), Acetyl‐CoA Carboxylase (ACC), Malic Enzyme (ME), Sterol Regulatory Element Binding Protein (SREBP), and Stearoyl‐CoA Desaturase (SCD) were determined via real time RT‐PCR and normalized to Acidic Ribosomal Protein. FAS enzyme activity was also determined as NADPH disappearance. CO increased the expression of ME (P &lt; 0.01), FAS (P &lt; 0.001), and SCD (P &lt; 0.001) but decreased the expression of ACC (P &lt; 0.01). CLA increased the expression of ME (P &lt; 0.001). Specifically, the CO+CLA‐fed mice had increased (P &lt; 0.05) ME and SCD mRNA and decreased (P &lt; 0.05) ACC mRNA vs all other diet groups. There was also an effect of day on SCD mRNA, where SCD expression increased (P &lt; 0.01) with increasing days on feed. SREBP mRNA and FAS enzyme activity were not different. It appears that CO‐feeding may cause an increase in fatty acid turnover that could contribute to the greater loss of body fat observed when these mice are fed CLA.

Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells

IntroductionThe human epidermal growth factor receptor 2 (HER2) is a validated therapeutic target in breast cancer. Heterodimerization of HER2 with other HER family members results in enhanced tyrosine phosphorylation and activation of signal transduction pathways. HER2 overexpression increases the translation of fatty acid synthase (FASN), and FASN overexpression markedly increases HER2 signaling, which results in enhanced cell growth. However, the molecular mechanism and regulation of HER2 and FASN interaction are not well defined. Lapatinib is a small-molecule tyrosine kinase inhibitor that blocks phosphorylation of the epidermal growth factor receptor and HER2 in breast cancer cells, resulting in apoptosis. We hypothesized that FASN is directly phosphorylated by HER2, resulting in enhanced signaling and tumor progression in breast cancer cells.MethodsUsing mass spectrometry, we identified FASN as one of the proteins that is dephosphorylated by lapatinib in SKBR3 breast cancer cells. Immunofluorescence, immunoprecipitation, Western blotting, a kinase assay, a FASN enzymatic activity assay, an invasion assay, a cell viability assay and zymography were used to determine the role of FASN phosphorylation in invasion of SKBR3 and BT474 cells. The FASN inhibitor C75 and small interfering RNA were used to downregulate FASN expression and/or activity.ResultsOur data demonstrated that FASN is phosphorylated when it is in complex with HER2. FASN phosphorylation was induced by heregulin in HER2-overexpressing SKBR3 and BT474 breast cancer cells. Heregulin-induced FASN phosphorylation resulted in increased FASN enzymatic activity, which was inhibited by lapatinib. The FASN inhibitor C75 suppressed FASN activity by directly inhibiting HER2 and FASN phosphorylation. Blocking FASN phosphorylation and activity by lapatinib or C75 suppressed the activity of matrix metallopeptidase 9 and inhibited invasion of SKBR3 and BT474 cells.ConclusionsFASN phosphorylation by HER2 plays an important role in breast cancer progression and may be a novel therapeutic target in HER2-overexpressing breast cancer cells.

Inhibition of Insulin and T3‐Induced Fatty Acid Synthase by Hexanoate

Fatty acid synthase (FAS) is responsible for the de novo synthesis of palmitate and stearate. This enzyme is activated by insulin and T(3), and inhibited by fatty acids. In this study, we show that insulin and T(3) have an inducing effect on FAS enzymatic activity, which is synergetic when both hormones are present. Octanoate and hexanoate specifically inhibit this hormonal effect. A similar inhibitory effect is observed at the level of protein expression. Transient transfections in HepG2 cells revealed that hexanoate inhibits, at least in part, FAS at a transcriptional level targeting the T(3) response element (TRE) on the FAS promoter. The effect of C6 on FAS expression cannot be attributed to a modification of insulin receptor activation or to a decrease in T(3) entry in the cells. Using bromo-hexanoate, we determined that hexanoate needs to undergo a transformation in order to have an effect. When incubating cells with triglyceride-hexanoate or carnitine-hexanoate, no effect on the enzymatic activity induced by insulin and T(3) is observed. A similar result was obtained when cells were incubated with betulinic acid, an inhibitor of the diacylglycerol acyltransferase. However, the incubation of cells with Triacsin C, a general inhibitor of acyl-CoA synthetases, completely reversed the inhibitory effect of hexanoate. Our results suggest that in hepatic cells, hexanoate needs to be activated into a CoA derivative in order to inhibit the insulin and T(3)-induced FAS expression. This effect is partially transcriptional, targeting the TRE on the FAS promoter.

The 10t,12c Isomer of Conjugated Linoleic Acid Inhibits Fatty Acid Synthase Expression and Enzyme Activity in Human Breast, Colon, and Prostate Cancer Cells

The objective of this study was to determine whether downregulation of fatty acid synthase (FAS) expression and/or inhibition of its activity by the two major CLA isomers, 10t,12c and 9c,11t CLA, could contribute to their inhibitory effect on the growth of human breast (MCF-7), colon (HT-29) and prostate (LNCaP) cancer cell lines. We first confirmed and extended the results of others showing that the inhibitory action of CLA on proliferation is dependent on the cell type as well as the structure of the isomer, the 10,12 isomer being a more potent inhibitor than the 9,11 isomer in the concentration range 25–100 μM. By Western analysis, we showed that 10,12 CLA downregulated FAS expression in all of the cell lines in a concentration-dependent manner, but the 9,11 isomer had no effect. Both isomers inhibited FAS enzyme activity, but 10,12 CLA was again more potent than the 9,11 isomer. Our results suggest that downregulation of FAS by 10,12 CLA, but not by the 9,11 isomer, as well as inhibition of FAS enzyme activity by both isomers, may contribute to growth inhibition of cancer cells but only at relatively high concentrations.

Pharmacological blockade of Fatty Acid Synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin™) by transcriptionally inhibiting ‘HER2 super-expression’ occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells

Elucidating the mechanisms underlying resistance to the human epidermal growth factor receptor 2 (HER2)-targeted antibody trastuzumab (Tzb; Herceptin) is a major challenge that is beginning to be addressed. This dilemma is becoming increasingly important as recent studies strongly support a role for Tzb in the adjuvant setting for HER2-overexpressing early-stage breast cancers. We previously reported that pharmacological and RNA interference-induced inhibition of tumor-associated fatty acid synthase (FASN; Oncogenic antigen-519), a key metabolic enzyme catalyzing the synthesis of long-chain saturated fatty acids, drastically down-regulates HER2 expression in human breast cancer cells bearing HER2 gene amplification. Given that FASN blockade was found to suppress HER2 overexpression by attenuating the promoter activity of the HER2 gene, we here envisioned that this mechanism of action may represent a valuable strategy in breast cancers that have progressed while under Tzb. We created a preclinical model of Tzb resistance by continuously growing HER2-overexpressing SKBR3 breast cancer cells in the presence of clinically relevant concentrations of Tzb (20-185 microg/ml Tzb). This pool of Tzb-conditioned SKBR3 cells, which optimally grows now in the presence of 100 microg/ml trastuzumab (SKBR3/Tzb100 cells), exhibited HER2 levels notably higher (approximately 2-fold) than those found in SKBR3 parental cells. Real-time polymerase chain reaction studies showed that up-regulation of HER2 mRNA levels closely correlated with HER2 protein up-regulation in SKBR3/Tzb100 cells, thus suggesting that 'HER2 super-expression' upon acquisition of autoresistance to Tzb resulted, at least in part, from up-regulatory effects in the transcriptional rate of the HER2 gene. SKBR3/Tzb100 cells did not exhibit cross-resistance to C75, a small-compound specifically inhibiting FASN activity. On the contrary, SKBR3/Tzb100 cells showed a remarkably increased sensitivity (approximately 3-fold) to the cytotoxic effects occurring upon C75-induced inhibition of FASN enzymatic activity. Both HER2 mRNA and HER2 protein 'super-expression', which have not been reported in earlier Tzb-resistant breast cancer models, were entirely suppressed following pharmacological blockade of FASN activity. Moreover, while Tzb was still able to reduce HER2 protein expression by approximately 20% in SKBR/Tzb100 cells, C75 and Tzb co-exposure synergistically down-regulated HER2 protein levels by >85%. The nature of the interaction between Tzb and C75 in Tzb-resistant SKBR3/Tzb100 cells was also found to be strongly synergistic when analyzing the extent of apoptotic cell death using ELISA-based detection of histone-associated DNA fragments. In summary, a) the molecular mechanism(s) contributing to Tzb resistance in our SKBR3/Tzb100 model appear to be clearly different to those previously reported as we found important transcriptional up-regulatory transcriptional changes in HER2 gene expression levels relative to parental cells; b) since FASN inhibition acts on HER2 gene expression via reduction of its transcription rate, Tzb-conditioned HER2-overexpressing breast cancer cells not only retain but further gain sensitivity to FASN inhibition; and c) transcriptional suppression of HER2 expression using FASN blockers may represent a new molecular strategy in the management of Tzb-resistant breast cancer disease.

Second-generation inhibitors of fatty acid synthase for lung cancer treatment

18185 Fatty acid synthase (FAS) is highly expressed in many human cancers, including lung cancers. Previous work has shown that blocking FAS activity by cerulenin, a natural antibiotic, or C75, a first-generation synthetic small molecule, leads to apoptosis in cells that overexpress this enzyme. However, the use of C75 is limited by the dose-dependent anorexia that appears to be associated with stimulation of fatty acid oxidation. Pharmacokinetics studies show that the activity of C75 peaks within hours of administration and by 24 hours, approximately 80% of activity is lost. Thus, the effectiveness of C75 is limited by this short duration of anti-neoplastic activity and the prolonged anorexic effects.Several second-generation novel FAS-inhibitory compounds have been synthesized that show significant inhibition of FAS, without parallel stimulation of fatty acid oxidation. Among the most promising of the compounds is C93, which inhibits FAS at nearly equal potency as C75, but has significantly less stimulation of fatty acid oxidation. We treated mice with xenografts (orthotopic and subcutaneous) developed from 3 different human lung cancer cell lines (H460, A549, and LX-7) with daily intraperitoneal injections of C93 (5 days/week) at 50 mg/kg for 4 weeks and observed significant (up to 70%) inhibition of tumor growth in all xenograft models tested. Furthermore, no significant weight loss and no organ-specific toxicity were recognized in treated animals. These results suggest that it is possible to pharmacologically uncouple inhibition of FAS from stimulation of fatty acid oxidation, and thus achieve anti-neoplastic activity by inhibition of FAS without significant drug-induced anorexia. Finally, we tested an oral formulation of C93 with the intent of developing a dosing protocol suitable for clinical applications. Similar levels of drug in tumor tissue, and similar inhibition of fatty acid synthase enzyme activity, were seen after oral and intraperitoneal administrations of drug. Furthermore, repeated oral administration of C93 to animals with subcutaneous H460 lung cancer xenografts inhibited tumor growth to a similar level observed after intraperitoneal administration. Thus, fatty acid synthase appears to be a promising target for lung cancer treatment. No significant financial relationships to disclose.

The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival

Overexpression of the lipogenic enzyme fatty acid synthase (FAS) is a common molecular feature in subsets of sex-steroid-related tumors including breast carcinomas that is associated with poor prognosis. In this study, we explored whether breast-cancer associated FAS (oncogenic antigen-519) is regulated by the progestin component in oral contraceptives. In addition, we examined the role of FAS hyperactivity on progestin-regulated breast cancer cell proliferation, survival and metastatic properties. We found that in estrogen receptor (ER)- and progesterone receptor (PR)-positive MCF-7 human breast cancer cells, synthetic progestins used in oral contraceptives including norethynodrel (NOR) and norethindrone, induced a dose-dependent increase of FAS enzymatic activity, with a maximum response (> or = 4-fold) occurring at a concentration of 10(-8) M. FAS activity was only slightly stimulated after exposure to two other progestins, medroxy-progesterone acetate (MPA) and megestrol acetate (MGA), which are used in postmenopausal hormone replacement therapy and high-dose progestin treatment therapy. Western blot analyses showed that NOR-induced stimulation of FAS activity correlated closely with NOR-induced up-regulation of FAS protein expression. To determine the role of FAS accumulation following NOR exposure, we pharmacologically examined the requirement for FAS activity in NOR-stimulated breast cancer cell proliferation and survival. The novel small compound C75 (a slow-binding FAS inhibitor) blocked NOR-induced breast cancer cell proliferation in anchorage-dependent assays. More importantly, pharmacological inhibition of FAS activity completely abolished NOR-stimulated soft-agar colony formation of MCF-7 cells. To evaluate the involvement of PR and ER signalings in NOR-induced up-regulation of FAS expression and activity, NOR was used in combination with either the anti-progestin RU486 (mifepristone) or the pure antiestrogen ICI 182,780 (Faslodex). RU486 and ICI 182,780 similarly abolished NOR-induced FAS activation, supporting the notion that PR- and ER-mediated FAS up-regulation might play different roles in NOR-stimulated breast cancer cells. Interestingly, when we evaluated the involvement of PR and ER signalings on NOR-induced breast cancer cell proliferation, the anti-estrogen ICI 182,780, but not the anti-progestin RU486, was found to inhibit NOR-stimulated proliferation and survival of MCF-7 cells in anchorage-dependent and -independent assays. To further determine whether NOR produced their effects via the ER, we evaluated its effects on endogenous ER transcriptional activity by using transient transfection assays with an estrogen-response element reporter construct (ERE-Luciferase). In the absence of E2 stimulation, treatment with NOR dramatically increased the levels of ERE-dependent transcriptional activity. This estrogenic like-effect of NOR was blocked by the addition of ICI 182,780, whereas RU486 failed to inhibit NOR-induced ERE activity. In summary, this study provides direct evidence that: a) a number of synthetic progestins used in oral contraceptives significantly activates breast cancer-associated FAS (OA-519) activity and expression in hormone-dependent breast cancer cells; b) FAS activity is necessary for progestin-induced anchorage-independent growth and survival of human breast cancer cells, and c) activation of ER, but not PR signaling, is the stimulatory mechanism through which synthetic progestins enhance a FAS-dependent proliferative and pro-survival signaling. These findings should be helpful to explain the conflicting evidence linking oral contraceptives and breast cancer risk through the estrogenic activation of tumor-associated FAS (OA-519), a molecular marker associated with poor clinical outcome of breast cancer disease.

Disconnection between the early onset anorectic effects by C75 and hypothalamic fatty acid synthase inhibition in rodents

In order to explore the relationship between the anorectic effect of 3-carboxy-4-octyl-2-methylenebutyrolactone (C75) and its pharmacokinetic properties, studies of in vivo and in vitro pharmacological characterization of C75 were performed in Fischer rats. In a quantitative measurement of food intake, we determined that appetite suppression by C75 takes place within 4 h. The C max for C75 of 2.6±1.5 μM was reached within 1–4 h after intraperitoneal administration at 30 mg/kg, a drug level that causes complete blockade of food intake. However, this concentration is substantially lower than the effective concentration used to inhibit rat fatty acid synthase enzyme activity in vitro (IC 50: ∼200 μM) and hypothalamic enzyme activity was found not to be inhibited by intraperitoneal administration of C75 at 30 mg/kg. Instead, a dramatic induction of c-Fos expression was found in area postrema. Collectively, these data indicate that the anorectic effect of C75 is independent of its inhibition of fatty acid synthase in the hypothalamus.

Modulation of lipogenic enzymes, fatty acid synthase and Δ 9 -desaturase, in relation to migration in the western sandpiper ( Calidris mauri )

Long-distance migration in birds is characterized physiologically by periods of rapid fattening and lipogenesis, and increased desaturation of fatty acids stored in adipose tissue. We investigated seasonal, age- and sex-related differences in activities of two lipogenic enzymes, fatty acid synthase and delta9-desaturase, in relation to migration in the small, Arctic-nesting western sandpiper (Calidris mauri). Migration, and associated lipogenesis and fattening, involved marked upregulation of these enzymes in this species. However, this increase in enzyme activity was only seen in actively migrating birds during spring migration, when fatty acid synthase and delta9-desaturase levels increased by 53% and 113%, respectively, compared to non-migrating birds. There was no change in fatty acid synthase enzyme activity during the premigration period, even though body mass of adult birds increased significantly during this period. Similarly, there was no increase in delta9-desaturase activity during premigration, despite the fact that birds increase the proportion of monounsaturated fatty acids in their fat stores at this time. We suggest that upregulation of lipogenic enzymes is required to support high rates of mass gain (0.4 g day(-1)) during short (1-4 day) periods at stop-over sites. However, slower rates of mass gain (0.09 g day(-1)) over several weeks prior to migration can be achieved without any increase in tissue-specific enzyme activity.

Exercise attenuates nuclear protein binding to gene regulatory sequences of hepatic fatty acid synthase.

The effect of an acute bout of exhaustive exercise on hepatic fatty acid synthase (FAS) gene expression was examined in rats. Female Sprague-Dawley rats (age 8 wk) were fasted for 48 h (F, n = 6), or fasted, refed a high-fructose diet for 6 h, and killed at rest (R, n = 6) or killed after running on a treadmill at 27 m/min and 5% grade for 88 +/- 7 min (E, n = 6). Gel mobility shift assay indicated that R rats had twofold higher liver nuclear protein binding to oligonucleotides corresponding to the insulin responsive sequence (-71/-50) and carbohydrate response element (+283/+303) on the FAS promoter, compared with F rats. Exercise severely attenuated this binding in liver nuclear extracts to the levels seen in F rats. Competition and supershift experiments revealed that the bound protein complexes contained the upstream stimulatory factors. Nuclear run-on experiment revealed a 49-fold increase in transcription rate of the FAS gene in R vs. F rats, whereas exercise suppressed the transcription rate. FAS mRNA abundance and FAS enzyme activity were dramatically increased with refeeding but were unaltered by exercise. The results reveal that dietary induction of hepatic FAS is stimulated by increased nuclear protein binding to insulin responsive sequence and carbohydrate response element, whereas exhaustive exercise attenuates the binding, which may precede downregulation of FAS mRNA and enzyme synthesis reported in our previous work (M. A. Griffiths, R. Fiebig, M. T. Gore, D. H. Baker, K. Esser, L. Oscai, and L. L. Ji. J. Nutr. 126, 1959-1971, 1996).